BCX-4208, a novel inhibitor of the enzyme purine nucleoside phosphorylase, mimics the charged ribosyl oxocarbenium ion formed during the transition state of the enzyme-catalyzed C-N bond cleavage of nucleosides. A slow-onset, tight-binding inhibitor with a Ki* of 16 ± 1.4 pM, BCX-4208 is one of the most potent inhibitors known for the enzyme. In support of our BCX-4208 clinical program, a mass spectrometric assay has been developed that required labeled BCX-4208 as an internal standard. The synthesis of [2H]2-BCX-4208 and [13C]-BCX-4208 is described in this report. Copyright © 2009 John Wiley & Sons, Ltd.
CITATION STYLE
Kamath, V. P., Juarez-Brambila, J. J., & Morris, P. E. (2009). Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Testing and Analysis, 1(3), 125–127. https://doi.org/10.1002/dta.24
Mendeley helps you to discover research relevant for your work.